NCBiotech News

Banner Life Sciences, a High Point pharmaceutical company, has gained final regulatory approval of a drug for treating multiple sclerosis.

Cambrex Corp., a global provider of small-molecule drug services with growing operations in High Point and Durham, has finished an expansion of its biopharmaceutical analysis capabilities in Durham.

FUJIFILM Diosynth Biotechnologies U.S.A. has broken ground on a $54 million, 31,778-square-foot expansion of its biomanufacturing facilities in Morrisville.

Alcami Corp., a contract development and manufacturing organization (CDMO) headquartered in Durham and with major operations in Wilmington, has expanded its drug-making capacity by acquiring TriPharm Services.

TriPharm Services, a new Morrisville-based contract pharmaceutical development and manufacturing organization, is commissioning a new specialized manufacturing operation using the latest isolator manufacturing equipment.

Durham contract services organization KBI Biopharma is working with two other companies to develop a novel therapy to treat inflammatory diseases.

Lindy Biosciences, a biotech company developing innovative drug formulation technology that was bootstrapped by a loan from the North Carolina Biotechnology Center, has now completed a $1.6M Series A round.

A north Raleigh drug-manufacturing site purchased in 2014 by Denmark-based Xellia Pharmaceuticals has been sold again -- this time to Sagent Pharmaceuticals of Schaumburg, Illinois.

Fujifilm Corp. will expand its biomanufacturing facilities in Morrisville as part of a $90 million investment in its contract development and manufacturing organization (CDMO) business to meet growing customer demand for biopharmaceuticals.

Charlotte's Bright Path Laboratories says it has found a better way to produce active pharmaceutical ingredients – those chemical components that make medicines work the way they’re supposed to.

Seqirus has received the go-ahead from the FDA to produce its Fluad Quadrivalent vaccine at its Holly Springs factory.

North Carolina’s biopharma manufacturing market is hot at the moment – with an estimated 5,000 new jobs projected for the sector by 2025, according to a recent study.

The newly published 2020 edition of the “Window on the Workplace” study analysis says North Carolina's long-term commitment to biopharma workforce readiness will need to adjust and grow to meet coming demand.

bluebird bio, a gene therapy company with operations in Durham, has launched for the first time its treatment for a severe inherited blood disorder, in Germany.

NCBiotech convened a panel of companies with operations in North Carolina at BIO-Europe 2019 to explore challenges that European life science companies face when setting up shop in the U.S.